In this video, Nancy U. Lin, MD, highlights practice-changing trials in the HER2-positive metastatic breast cancer space.

Delhi High Court refuses to direct Zydus to disclose manufacturing process of Sigrima: Gireesh Babu, New Delhi Saturday, July 26, 2025, 08:00 Hrs [IST] The Delhi High Court has sa ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

In this video, Nancy U. Lin, MD, discusses curative intent research in HER2-positive metastatic breast cancer.

As researchers keep looking for ways to deescalate treatment in HER2-positive breast cancer, a trial from China looked at a chemotherapy-free regimen with endocrine therapy, a CDK4/6 inhibitor, and ...

Roche’s Itovebi gets European approval to treat people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation: Basel Thursday, July 24, 2025, 09:00 Hrs [ ...

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

Q2 2025 has demonstrated the pharmaceutical industry’s continued momentum in developing transformative therapies across ...

Overview of Breast Cancer Therapeutics MarketThe Global Breast Cancer Therapeutics Market is valued at USD 33.83 Billion in ...

Roche’s oral PI3K inhibitor Itovebi (inavolisib) has been approved by the European Commission (EC) as part of a combination treatment for advanced breast cancer patients.

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and Roche's HER2 antibody, Perjeta (pertuzumab), to the widely used THP ...

As first-line treatments in metastatic HER2-positive breast cancer evolve, the firm expects its HER2 targeted therapies to remain integral to growth.